Dr. Steven W. Pipe, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 78
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MI license 4301061199 -
Pediatrics Physician
MI license 4301061199
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 91
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Coagulation function screening test with interpretation and report | 66 | 64 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 15 companies reported 123 payments worth $251,232 in total to this clinician.
| Genzyme Corporation | $84,324 |
|---|---|
| Csl Behring | $30,539 |
| Pfizer Inc. | $23,500 |
| Chugai Pharmaceutical Co., LTD. | $19,936 |
| BioMarin Pharmaceutical Inc. | $18,207 |
| Novo Nordisk Inc | $15,448 |
| Ultragenyx Pharmaceutical Inc. | $14,564 |
| Regeneron Pharmaceuticals, Inc. | $13,284 |
| Compensation for services other than consulting (speaking, faculty) | $125,315 |
|---|---|
| Consulting Fee | $109,046 |
| Travel and Lodging | $15,355 |
| Food and Beverage | $1,516 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $20,937 |
| Genzyme Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $16,144 |
| Ultragenyx Pharmaceutical Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind | $13,302 |
| Chugai Pharmaceutical Co., LTD. May 19, 2025 | Consulting Fee | $13,120 |
| Genzyme Corporation Dec 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,177 |
| Genzyme Corporation Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,275 |
| Csl Behring Oct 5, 2025 | Travel and Lodging travel to SEVILLE, Spain · in-kind | $9,922 |
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $8,679 |
| Pfizer Inc. Mar 31, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $7,500 |
| Csl Behring Jun 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,140 |
All 105 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| Genzyme Corporation Dec 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,177 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $625 |
| BioMarin Pharmaceutical Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) ROCTAVIAN · Hemophilia A | $1,782 |
| Pfizer Inc. Dec 19, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $625 |
| Csl Behring Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $939 |
| Csl Behring Dec 7, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $722 |
| F. Hoffmann-la Roche AG Dec 5, 2025 | Consulting Fee Hemlibra · Hematology | $4,100 |
| Genentech USA, Inc. Dec 5, 2025 | Consulting Fee Hemlibra · Hematology | $1,640 |
| Regeneron Pharmaceuticals, Inc. Nov 21, 2025 | Consulting Fee | $927 |
| Genentech, Inc. Nov 19, 2025 | Consulting Fee Hemlibra · Hematology | $1,520 |
| Pfizer Inc. Nov 19, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,250 |
| Csl Behring Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $1,059 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $2,500 |
| Csl Behring Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $810 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $927 |
| Pfizer Inc. Nov 4, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,875 |
| Pfizer Inc. Nov 4, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,250 |
| Genzyme Corporation Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $20,937 |
| Genzyme Corporation Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,766 |
| Pfizer Inc. Oct 30, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $625 |
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $8,679 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $413 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $282 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $204 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $28.14 |
| Novo Nordisk Inc Oct 23, 2025 | Consulting Fee | $2,620 |
| Genzyme Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $16,144 |
| Csl Behring Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $444 |
| Regeneron Pharmaceuticals, Inc. Oct 10, 2025 | Consulting Fee | $1,658 |
| Csl Behring Oct 7, 2025 | Travel and Lodging travel to SEVILLE, Spain · in-kind | $472 |
| Csl Behring Oct 7, 2025 | Travel and Lodging travel to SEVILLE, Spain · in-kind | $149 |
| Csl Behring Oct 5, 2025 | Travel and Lodging travel to SEVILLE, Spain · in-kind | $9,922 |
| Csl Behring Oct 5, 2025 | Travel and Lodging travel to SEVILLE, Spain · in-kind | $194 |
| Regeneron Pharmaceuticals, Inc. Sep 5, 2025 | Consulting Fee | $2,781 |
| Regeneron Pharmaceuticals, Inc. Sep 5, 2025 | Consulting Fee | $1,854 |
| Regeneron Pharmaceuticals, Inc. Sep 5, 2025 | Consulting Fee | $1,159 |
| Csl Behring Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $1,068 |
| Regeneron Pharmaceuticals, Inc. Sep 5, 2025 | Consulting Fee | $695 |
| Csl Behring Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,094 |
| Pfizer Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $1,500 |
| Csl Behring Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $523 |
| Csl Behring Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $403 |
| Csl Behring Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $259 |
| Genzyme Corporation Jul 17, 2025 | Consulting Fee | $777 |
| F. Hoffmann-la Roche AG Jul 1, 2025 | Consulting Fee | $760 |
| Csl Behring Jun 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,140 |
| Novo Nordisk Inc Jun 27, 2025 | Consulting Fee | $2,948 |
| Regeneron Pharmaceuticals, Inc. Jun 27, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $136 |
| Samsung Bioepis Co., LTD. Jun 26, 2025 | Consulting Fee SB39 · Hematology | $2,000 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,592 |
| Roche Products Limited Jun 23, 2025 | Consulting Fee | $2,460 |
| Genzyme Corporation Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,592 |
| Genzyme Corporation Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,703 |
| Chugai Pharmaceutical Co., LTD. Jun 21, 2025 | Consulting Fee | $4,920 |
| Genentech USA, Inc. Jun 20, 2025 | Consulting Fee Hemlibra · Hematology | $1,640 |
| Regeneron Pharmaceuticals, Inc. Jun 20, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $136 |
| Chugai Pharmaceutical Co., LTD. May 19, 2025 | Consulting Fee | $13,120 |
| Chugai Pharmaceutical Co., LTD. May 19, 2025 | Travel and Lodging travel to Tokyo&Osaka, Japan | $1,388 |
| Chugai Pharmaceutical Co., LTD. May 19, 2025 | Travel and Lodging travel to Tokyo&Osaka, Japan | $335 |
| Ultragenyx Pharmaceutical Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind | $13,302 |
| Ultragenyx Pharmaceutical Inc. May 5, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind | $1,262 |
| Genzyme Corporation Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| Csl Behring Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,697 |
| Regeneron Pharmaceuticals, Inc. Apr 16, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $35.50 |
| Pfizer Inc. Apr 14, 2025 | Consulting Fee | $2,250 |
| Pfizer Inc. Apr 2, 2025 | Consulting Fee | $2,750 |
| Novo Nordisk Health Care AG Apr 1, 2025 | Consulting Fee NovoSeven · Hemophilia | $6,550 |
| Pfizer Inc. Mar 31, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $7,500 |
| Regeneron Pharmaceuticals, Inc. Mar 20, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $374 |
| Regeneron Pharmaceuticals, Inc. Mar 20, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $25.50 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) FEIBA · HEMATOLOGY · in-kind | $5,046 |
| Genzyme Corporation Mar 15, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| F. Hoffmann-la Roche AG Mar 7, 2025 | Consulting Fee Hemlibra · Hematology | $1,140 |
| F. Hoffmann-la Roche AG Mar 7, 2025 | Consulting Fee Hemlibra · Hematology | $1,140 |
| Genzyme Corporation Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,275 |
| Roche Products Limited Feb 5, 2025 | Consulting Fee | $2,870 |
| Csl Behring Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $681 |
| Csl Behring Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $308 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $1,658 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $829 |
| Csl Behring Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $195 |
| Csl Behring Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $156 |
| Pfizer Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $339,469 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06379789 - Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Csl Behring · Recruiting · NCT07080905 - An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors
Genentech, Inc. - HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
Csl Behring · Completed · NCT03569891 - Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Csl Behring · Recruiting · NCT06003387 - Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Csl Behring · Enrolling by invitation · NCT05962398 - BMN 270-401
BioMarin Pharmaceutical Inc. - A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05568459
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.